Efbemalenograstim alfa-vuxw: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 April 2024

  • curprev 07:3407:34, 17 April 2024‎ Edzelco talk contribs‎ 20,126 bytes 0‎ No edit summary
  • curprev 07:3307:33, 17 April 2024‎ Edzelco talk contribs‎ 20,126 bytes +51‎ No edit summary
  • curprev 07:3207:32, 17 April 2024‎ Edzelco talk contribs‎ 20,075 bytes +20,075‎ Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle...."
Retrieved from "https://www.wikidoc.org/index.php/Efbemalenograstim_alfa-vuxw"